Skip to main content

Advertisement

SpringerLink
Log in

Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745–2760

    Article  CAS  Google Scholar 

  2. Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95(9):1526–1533

    Article  Google Scholar 

  3. Robak E, Robak T (2007) Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 48:855–865

    Article  Google Scholar 

  4. Cerroni L, Zenahlik P, Höfler G, Kaddu S, Smolle J, Kerl H (1996) Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: a clinicopathologicand prognostic study of 42 patients. Am J Surg Pathol 20(8):1000–1010

    Article  CAS  Google Scholar 

  5. Aldapt MB, Yassin M (2021) Leukemia cutis as an early presentation or relapsing manifestation of chronic lymphocytic leukemia (CLL). Acta Biomed 92(2):e2021192

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Albano D, Luca Camoni L, Rodella C, Giubbini R, Bertagna F (2020) 12-[18F]-FDG PET/CT role in detecting richter transformation of chronic lymphocytic leukemia and predicting overall survival. Clin Lymphoma Myeloma Leuk 21(3):e277-283

    Article  Google Scholar 

  7. Agbay RL, Jain N, Loghavi S, Medeiros LJ, Khoury JD (2016) Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 91(10):1036–1043

    Article  Google Scholar 

  8. Asplund SL, McKenna RW, Howard MS, Kroft SH (2002) Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Surg Pathol 26(5):624–629

    Article  Google Scholar 

  9. Ciccone M, Agostinelli C, Rigolin GM, Piccaluga PP, Cavazzini F, Righi S, Sista MT, Sofritti O, Rizzotto L, Sabattini E, Fioritoni G, Falorio S, Stelitano C, Olivieri A, Attolico I, Brugiatelli M, Zinzani PL, Saccenti E, Capello D, Negrini M, Cuneo A, Pileri S (2012) Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Leukemia 26(3):499–508

    Article  CAS  Google Scholar 

  10. Colburn DE, Welch MA, Giles FJ (2002) Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis. Hematology 7(3):187–188

    Article  Google Scholar 

Download references

Acknowledgements

We thank Edward Lowczowski from the Medical University of Lodz for editorial assistance and Aleksandra Samulska for technical assistance. We also thank Dr Ewa Wawrzyniak for performing genetic analysis and Maciej Naze MD, PhD, for providing PET/CT images. We are grateful to the medical, nursing, and laboratory staff of the participating departments for their contributions to this study.

Author information

Authors and Affiliations

  1. Department of Dermatology, Medical University of Lodz, Lodz, Poland

    Ewa Robak

  2. Department of Pathology, Medical University of Lodz, Lodz, Poland

    Dorota Jesionek-Kupnicka

  3. Copernicus Memorial Hospital, Lodz, Poland

    Piotr Stelmach, Piotr Kupnicki, Magdalena Szataniak & Tadeusz Robak

  4. Department of Radiology and Diagnostic Imaging, Medical University of Lodz, Lodz, Poland

    Piotr Kupnicki

  5. Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, Lodz, Poland

    Tadeusz Robak

Authors
  1. Ewa Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorota Jesionek-Kupnicka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piotr Stelmach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Piotr Kupnicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Magdalena Szataniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tadeusz Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadeusz Robak.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from the patient included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Robak, E., Jesionek-Kupnicka, D., Stelmach, P. et al. Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab. Ann Hematol 101, 1387–1392 (2022). https://doi.org/10.1007/s00277-022-04753-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04753-7

Search

Navigation